Live tape
Top 8, mentions 7d6,813META1,898 mentions▲ +0.06GOOGL1,411 mentions▲ +0.02NVDA814 mentions▲ +0.09MSFT594 mentions▲ +0.06TSLA550 mentions▲ +0.05SPY528 mentions▲ +0.04MUSE525 mentions▲ +0.06AMZN493 mentions▲ +0.03

Equity · Healthcare

ALNY

NASDAQ

Alnylam Pharmaceuticals, Inc.

$255.37 −0.21% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 28, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$350 $200 1 Jul 28 Sep

The line runs $301.70 on 1 July through $255.37 on 28 September, on a scale from $200 to $350. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ALNY over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $301.70 on 1 July 2026 through $255.37 on 28 September 2026.

Market cap $34.2B
P/E (TTM) 109.6
52-week range $203 – $491
Avg volume 116.4K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 28, 2026

ALNY insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 19 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
19 Sep 2026 Greenstreet Yvonne Chief Executive Officer Award 107

ALNY reported financials

SEC EDGAR XBRL

ALNY reported revenue of $3.7B for the fiscal year ended 31 Dec 2025. Net income over the same period was $313.7M.

Figure Reported Period
Revenue $3.7B 31 Dec 2025 fiscal year
Net income $313.7M 31 Dec 2025 fiscal year
Diluted EPS $2.33 31 Dec 2025 fiscal year
Total assets $5.6B 30 Jun 2026 at period end
Total equity $1.4B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ALNY earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.21 —
31 Dec 2025 FY 2025 $2.33 —
30 Sep 2025 FY 2025 $1.51 —
30 Jun 2025 FY 2025 $-0.70 —
31 Mar 2025 FY 2025 $-0.14 —
31 Dec 2024 FY 2024 $-2.18 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ALNY institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a ALNY position for the quarter ended 30 Jun 2026 — a combined $1.5B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −5.9% shares 1,875,937 $564.7M
D. E. Shaw & Co. Held (±25%) +4.3% shares 1,104,109 $332.4M
AQR Capital Management Held (±25%) −20.3% shares 728,039 $219.0M
Millennium Management Trimmed −29.4% shares 316,001 $95.1M
Marshall Wace Trimmed −76.4% shares 259,799 $78.2M
Citadel Advisors Added +715.8% shares 191,029 $57.5M
Man Group Trimmed −26.5% shares 170,907 $51.4M
Bridgewater Associates Held (±25%) −6.6% shares 99,584 $30.0M
Balyasny Asset Management New position 89,510 $26.9M
Fisher Asset Management Held (±25%) +3.4% shares 6,252 $1.9M

Source: SEC EDGAR 13F filings

ALNY fails-to-deliver

SEC CNS data

On 26 Aug 2026, 3 shares of ALNY failed to deliver (about $720).

Settlement date Shares failed Notional % of shares out
26 Aug 2026 3 $720 <0.001%
21 Aug 2026 297 $68K <0.001%
20 Aug 2026 19,753 $4.8M 0.015%

Source: SEC fails-to-deliver (CNS) data